<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782271</url>
  </required_header>
  <id_info>
    <org_study_id>SYL1801_I</org_study_id>
    <nct_id>NCT04782271</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetic Profile of Different Doses of SYL1801 Ophthalmic Solution in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sylentis, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sylentis, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801&#xD;
      eye drops in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">January 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Interventional, observer-masked, parallel groups, time-lagged trial to study safety, tolerability and PK of SYL1801 sodium in healthy volunteers.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular tolerability at the site of administration (cornea and conjunctiva) after last instillation of the assigned dose level (1 day of treatment).</measure>
    <time_frame>72 hours after last instillation</time_frame>
    <description>Slit lamp evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular tolerability at the site of administration (cornea and conjunctiva) after last instillation of the assigned dose level (7 days of treatment).</measure>
    <time_frame>72 hours after last instillation</time_frame>
    <description>Slit lamp evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the maximum Plasma Concentration [Cmax]</measure>
    <time_frame>- 15 - 30 minutes, 1- 4 and 24 hours after last administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the Area Under the Curve of plasma concentrations until the last extraction time [AUT 0-t]</measure>
    <time_frame>- 15 - 30 minutes, 1- 4 and 24 hours after last administration</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Single administration Low Dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 treatment day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single administration Middle Dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 treatment day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single administration High Dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 treatment day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single administration High Dose twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 treatment day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple administrations Low Dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 treatment days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple administrations Middle Dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 treatment days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple administrations High Dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 treatment days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple administrations High Dose twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 treatment days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL18001 sodium Low dose q.d</intervention_name>
    <description>1 drop in the randomized eye once daily</description>
    <arm_group_label>Multiple administrations Low Dose once daily</arm_group_label>
    <arm_group_label>Single administration Low Dose once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL18001 sodium Middle dose q.d</intervention_name>
    <description>1 drop in the randomized eye once daily</description>
    <arm_group_label>Multiple administrations Middle Dose once daily</arm_group_label>
    <arm_group_label>Single administration Middle Dose once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL18001 sodium High dose q.d</intervention_name>
    <description>1 drop in the randomized eye once daily</description>
    <arm_group_label>Multiple administrations High Dose once daily</arm_group_label>
    <arm_group_label>Single administration High Dose once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL18001 sodium High dose b.i.d</intervention_name>
    <description>1 drop in the randomized eye twice daily</description>
    <arm_group_label>Multiple administrations High Dose twice daily</arm_group_label>
    <arm_group_label>Single administration High Dose twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Body mass index (BMI) between 19.5 and 29.0 kg/m2&#xD;
&#xD;
          -  Intraocular pressure (IOP) &lt;=21 mmHg&#xD;
&#xD;
          -  Best Corrected Visual Acuity (BCVA) &gt;= 70 ETDRS&#xD;
&#xD;
          -  Normal corneal and conjunctival assessment&#xD;
&#xD;
          -  Normal funduscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding females or those with a positive pregnancy test. Females of&#xD;
             childbearing potential who will not use a medically acceptable contraceptive method&#xD;
&#xD;
          -  Current relevant diseases according to the investigator's judgement.&#xD;
&#xD;
          -  Previous relevant chronic processes according to the investigator's judgement&#xD;
&#xD;
          -  Relevant visual alterations according to the investigator's judgement&#xD;
&#xD;
          -  Administration of systemic medications&#xD;
&#xD;
          -  Case history of hypersensitivity to medicinal products or any other allergic process&#xD;
&#xD;
          -  Participation in any clinical study with an investigational drug/device within 3&#xD;
             months prior to the first day of dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Regulatory Affairs Department</last_name>
    <phone>918047667</phone>
    <email>info@sylentis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sylentis Clinical Trial Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligonucleotide</keyword>
  <keyword>siRNA (Small Interfering Ribonucleic Acid)</keyword>
  <keyword>Eye Drops</keyword>
  <keyword>wet AMD (Age-related Macular Degeneration)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

